Compare GREE & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GREE | NNVC |
|---|---|---|
| Founded | 1937 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | GREE | NNVC |
|---|---|---|
| Price | $1.64 | $1.28 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 254.7K | ★ 342.9K |
| Earning Date | 03-31-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,115,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $0.94 |
| 52 Week High | $2.42 | $2.23 |
| Indicator | GREE | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 53.05 |
| Support Level | $1.45 | $1.20 |
| Resistance Level | $1.75 | $1.31 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 55.88 | 67.24 |
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center. Company operates in three segments: Crypto Mining, Datacenter Hosting, Power and Capacity. The company owns and operates facilities at two locations: the Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.